Aquestive Therapeutics, Inc. introduced as we speak that the US Meals and Drug Administration (FDA) issued a Full Response Letter (CRL) concerning the New Drug Utility (NDA) for Anaphylm™ (dibutepinephrine). A CRL is an official communication from the FDA to a pharmaceutical firm indicating {that a} New Drug Utility (NDA) won’t be accepted in its present type. It outlines the particular deficiencies and points the company recognized throughout its evaluation that should be addressed earlier than the applying can proceed.
The sublingual movie is designed as a non-invasive therapy for Kind I allergic reactions, together with anaphylaxis, in sufferers weighing 30kg or extra. Though the CRL marks a regulatory setback, the corporate emphasised that the FDA’s considerations are restricted to particular areas somewhat than the drug’s elementary security or efficacy.
The first deficiencies cited by the FDA contain human elements (HF) validation and administration. Particularly, the Company famous cases by which members had issue opening the product’s pouch or putting the movie incorrectly. The FDA expressed concern that these points, if left unaddressed, may pose vital security dangers throughout an emergency anaphylactic occasion. Notably, the CRL didn’t increase considerations concerning the drug’s Chemistry, Manufacturing, and Controls (CMC) or the comparability information beforehand submitted.
In response to the suggestions, Aquestive has already begun modifying the pouch opening mechanism, labeling, and directions to be used. To fulfill the FDA’s necessities, the corporate plans to conduct a brand new HF validation research and a single pharmacokinetics (PK) research to verify that these packaging modifications don’t have an effect on drug supply. CEO Daniel Barber remained optimistic, stating, “Whereas it’s unlucky to have acquired a CRL, we consider that, with the readability we now have from the FDA, we have now made vital progress towards approval.”
The corporate intends to maneuver shortly and has requested a Kind A gathering with the FDA to align on probably the most environment friendly path ahead. Aquestive estimates will probably be able to resubmit the NDA as early because the third quarter of 2026, assuming research are accomplished on schedule. Administration reiterated its confidence within the product’s potential, with Barber including, “We stay assured within the effectiveness and security of Anaphylm and its potential as an easy-to-use, easy-to-carry, fast-acting epinephrine therapy”.
Medical professionals concerned within the scientific program additionally voiced continued help for the platform. Dr Jay Lieberman, a training allergist and investigator, famous that the FDA’s focus is totally on the “affected person expertise” somewhat than scientific failure. Lieberman remarked, “Given the continued underuse of epinephrine in anaphylaxis, the provision of extra therapy choices stays a high precedence for clinicians and the allergy neighborhood.”
Past america, Aquestive is sustaining its world enlargement timeline. The corporate plans to submit advertising purposes in Canada and the European Union within the second half of 2026. The European Medicines Company (EMA) has already indicated that no extra scientific trials shall be required for the submission. Financially, the corporate reported that it stays well-capitalized to fund the rest of the US approval course of and its worldwide ambitions.
Anaphylm represents a big departure from conventional epinephrine supply, using a polymer matrix-based movie concerning the measurement of a postage stamp. It dissolves on contact with out the necessity for water or swallowing, providing a transportable, needle-free different to auto-injectors. Aquestive will host an investor convention name on February 2, 2026, to debate these regulatory developments in additional element.
